ACRUX LIMITED — Capital/Financing Update 2014

Jan 30, 2014

ACRUX (ACR) - ASX ANNOUNCEMENT

31 JANUARY 2014

AXIRON NET SALES FOR CALENDAR YEAR 2013

Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of US$53.9 million in its financial results for the quarter ended 31 December 2013, up from US$40.6 million for the previous quarter to 30 September 2013.

Global Axiron net sales for the 2013 calendar year are shown in the following table:

Q1 2013	Q2 2013	Q3 2013	Q4 2013	Total for 2013
US$37.1m	US$47.1m	US$40.6m	US$53.9m	US$178.7m

In addition to royalties on these net sales, Acrux will receive a milestone payment of US$25 million in March 2014, as the worldwide net sales of Axiron in the 2013 calendar year exceeded US$100 million. As advised previously, funds that are superfluous to working capital requirements will be distributed to shareholders as dividends. We remain confident about the net sales growth prospects for calendar 2014.

Contact

Ross Dobinson, Executive Chairman: 03 9691 5920

About Acrux

www.acrux.com.au

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.

• Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [105 x 67] intentionally omitted <==